non responders to semaglutide GLP-1 nonresponders: Up 1 in 5 people don't lose weight Unfortunately up to 20% of

When appetite rebounds abruptly, rebound hunger can increase the likelihood of rapid weight regain

Here are some tips to keep in mind

How can providers manage medication adherence for GLP-1s

38 The Pharmaceutical Benefits Advisory Committee has recently recommended semaglutide 2.4 mg be listed on the PBS for adults with established cardiovascular disease and BMI 35 kg/m 2 or higher, or 32.5 kg/m 2 or higher for Asian, Aboriginal or Torres Strait Islander populations

The increasing development and regulatory approval of injectable biologics and vaccines further fuel demand for advanced prefilled syringes, including Ready-To-Use (RTU) options